Results 291 to 300 of about 1,770,471 (326)

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer.

Blood
Zeisig BB, Tsai CT, Virely C, Fung TK, Akin AT, Troadec E, Jiao B, Thompson IR, Thompson IR, Lau PNI, Li N, Charalambous A, Bomfim L, Lynch J, Georgiou A, Hoogeboom R, Lynn C, Zhang SY, Patten PEM, Fisher CL, Schuh A, Ogawa S, Mufti G, Karimi MM, So CWE.   +24 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Complex synthetic lethality in cancer

Nature Genetics, 2023
The concept of synthetic lethality has been widely applied to identify therapeutic targets in cancer, with varying degrees of success. The standard approach normally involves identifying genetic interactions between two genes, a driver and a target. In reality, however, most cancer synthetic lethal effects are likely complex and also polygenic, being ...
Colm J. Ryan, Lovely Paul Solomon Devakumar, S. Pettitt, C. Lord   +3 more
semanticscholar   +3 more sources

What’s next for the synthetic lethality drug discovery engine?

Nature Reviews Drug Discovery, 2022
Asher Mullard
exaly   +2 more sources

Synthetic lethality as an engine for cancer drug target discovery

Nature Reviews Drug Discovery, 2019
Alan Huang, Levi A Garraway, Alan Ashworth   +2 more
exaly   +2 more sources

Synthetic lethality and cancer

Nature Reviews Genetics, 2017
A synthetic lethal interaction occurs between two genes when the perturbation of either gene alone is viable but the perturbation of both genes simultaneously results in the loss of viability. Key to exploiting synthetic lethality in cancer treatment are the identification and the mechanistic characterization of robust synthetic lethal genetic ...
Nigel J O'Neil, Philip Hieter
exaly   +3 more sources

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.

Journal of Medicinal Chemistry, 2022
The effective potency and resistance of poly(ADP-ribose) polymerase (PARP) inhibitors limit their application. Here, we exploit a new paradigm that mimics the effects of breast cancer susceptibility genes (BRCA) mutations to trigger the possibility of ...
Jifa Zhang, Chengcan Yang, Pan Tang, Juncheng Chen, Dan Zhang, Yang Li, Gaoxia Yang, Yun Liu, Yiwen Zhang, Yuxi Wang, Jie Liu, L. Ouyang   +11 more
semanticscholar   +1 more source

Synthetic Lethal Screen

2005
The synthetic lethal screen is a method of isolating novel mutants whose survival is dependent on a gene of interest. Combining the colony-color assay with a synthetic lethal screen offers a means to visually detect a mutant that depends on a plasmid for survival. Screening for synthetic lethals can be achieved in four steps.
Leslie, Barbour, Wei, Xiao
openaire   +2 more sources

Searching for synthetic lethality in cancer

Current Opinion in Genetics & Development, 2011
The incentive to develop personalised therapy for cancer treatment is driven by the premise that it will increase therapeutic efficacy and reduce toxicity. Understanding the underlying cellular and molecular basis of the disease has been extremely important in the design of these novel therapies; however, identifying new drug targets for personalised ...
Rachel, Brough, Jessica R, Frankum, Sara, Costa-Cabral, Christopher J, Lord, Alan, Ashworth   +4 more
openaire   +2 more sources

Synthetic dosage lethality

2002
Publisher Summary Identification of proteins that interact to perform a common function is crucial to understanding the mechanisms of cellular processes. Both genetic and biochemical methods are used to uncover an interaction between two proteins. In yeast, many genetic screens have been developed, which begin with the mutation of a gene of interest ...
Vivien, Measday, Philip, Hieter
openaire   +2 more sources

Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer.

Cell Metabolism
Metabolic reprogramming is key for cancer development, yet the mechanism that sustains triple-negative breast cancer (TNBC) cell growth despite deficient pyruvate kinase M2 (PKM2) and tumor glycolysis remains to be determined.
Yingsheng Zhang, Meng-Ju Wu, Wan-Chi Lu, Yi-Chuan Li, Chun-Ju Chang, Jer-Yen Yang   +5 more
semanticscholar   +1 more source